<DOC>
	<DOC>NCT00350038</DOC>
	<brief_summary>The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.</brief_summary>
	<brief_title>Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Ciprofibrate</mesh_term>
	<criteria>hypertensive + dyslipidemic + damaged endothelial function hepatic and kidney damage, IDDM (Insulin Dependent Diabetes Mellitus) Freckson V type hyperlipoproteinaemia The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>